ARCT-021

This article is about the American vaccine. For other uses, see Arcturus COVID-19 vaccine.

ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.

ARCT-021

Vaccine description
Target	SARS-CoV-2
Vaccine type	sa-mRNA
Clinical data
Other names	LUNAR-COV19
Routes of administration	Intramuscular
Identifiers
CAS Number	2541451-24-3[1]

Medical uses

It requires the intramuscular injection with a single dose.^[2]

Pharmacology

ARCT-021 is an self-amplifying mRNA vaccine.^[3][4]

History

Arcturus Therapeutics partnered with Singapore's Duke–NUS Medical School to develop a COVID-19 vaccine.^[5] The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.^[6]

Clinical trials

LUNAR-COV19 clinical trials in humans began in July 2020.^[7] On 4 January 2021, Arcturus Therapeutics started Phase-2 clinical trials.^[8]

Economics

Arcturus has entered into development and supply agreements with the Economic Development Board of Singapore and supply agreements with the Israel Ministry of Health for LUNAR-COV19.^[9][10]